A PHASE II STUDY of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90–120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity. m-AMSA has little activity in patients with gastric adenocarcinoma.
From the Solid Tumor (PPS, GBM, DPK) and Developmental Chemotherapy (RJG) Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York.